⌕
Tyra Biosciences · TYRA · Nasdaq
Tenet 65 · Solid
Compare
$19.57−0.86%At closeTenet 65 · Solid
$19.57−0.17 (−0.86%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Tyra Biosciences (TYRA) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

The percentage on each card is TYRA's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

● PRNewsWireNov 10, 2026 · 08:00 ETCOMPANY'S OWN WORDS
Tyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights

Reported initial Phase 2 SURF302 results for oral dabogratinib in FGFR3-altered low-grade IR NMIBC patients Completed $400 million financing, providing additional capital to advance dabogratinib's 3x3 strategy Cash runwa…

TYRA −0.9% todayRead at source ↗
● PRNewsWireNov 5, 2026 · 16:05 ETCOMPANY'S OWN WORDS
Tyra Biosciences to Participate in Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fi…

TYRA −0.9% todayRead at source ↗
● PRNewsWireOct 15, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).  Such investors are advised to contact Danielle Pey…

TYRA −0.9% todayRead at source ↗
● Zacks Investment ResearchOct 14, 2026 · 10:36 ET
Here's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks

Tyra Biosciences (TYRA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead t…

TYRA −0.9% todayRead at source ↗
● PRNewsWireOct 8, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA). Such investors are advised to contact Danielle Peyto…

TYRA −0.9% todayRead at source ↗
● PRNewsWireOct 1, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).  Such investors are advised to contact Danielle Peyt…

TYRA −0.9% todayRead at source ↗
● Defense WorldSep 25, 2026 · 03:17 ET
Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the fourteen research firms that are covering the stock, Marketbeat reports. One investment analys…

TYRA −0.9% todayRead at source ↗
● PRNewsWireSep 17, 2026 · 10:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyra Biosciences, Inc. ("Tyra" or the "Company") (NASDAQ: TYRA).…

TYRA −0.9% todayRead at source ↗
● PRNewsWireSep 14, 2026 · 06:45 ET
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

CARLSBAD, Calif., Sept. 14, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in …

TYRA −0.9% todayRead at source ↗
● GuruFocusSep 10, 2026 · 20:00 ET
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRAPR NewswireNEW YORK, Sept. 10, 2026NEW YORK, Sept.…

TYRA −0.9% todayRead at source ↗
● Seeking AlphaSep 10, 2026 · 10:47 ET
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript

Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript…

TYRA −0.9% todayRead at source ↗
● BenzingaSep 9, 2026 · 12:39 ET
Why Is Tyra Biosciences Stock Sinking Wednesday?

Tyra Biosciences Inc. (NASDAQ:TYRA) stock is trading lower on Wednesday after the company shared initial results from its Phase 2 SURF302 trial evaluating oral dabogratinib, delivering clinical proof of concept and ident…

TYRA −0.9% todayRead at source ↗
● Investors Business DailySep 9, 2026 · 10:53 ET
Tyra Plummets To 10-Month Low On Mixed Bladder Cancer Results

Tyra stock plummeted to a 10-month low Wednesday on mixed test results for its experimental bladder cancer treatment.…

TYRA −0.9% todayRead at source ↗
● BarronsSep 9, 2026 · 10:44 ET
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Tyra Biosciences and Johnson & Johnson are pursuing their own approaches to treating a common, early-stage form of bladder cancer.…

TYRA −0.9% todayRead at source ↗
● PRNewsWireSep 9, 2026 · 07:00 ET
Tyra Biosciences Reports Initial Phase 2 SURF302 Results Supporting the First Potential Oral Innovation in LG IR NMIBC with Dabogratinib

CARLSBAD, Calif., Sept. 9, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in F…

TYRA −0.9% todayRead at source ↗
● PRNewsWireSep 8, 2026 · 16:05 ET
Tyra Biosciences to Present at the Cantor Global Healthcare Conference

CARLSBAD, Calif., Sept. 8, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in F…

TYRA −0.9% todayRead at source ↗
● Seeking AlphaSep 6, 2026 · 11:14 ET
Tyra Biosciences: 'Hold' IR-NMIBC Data September 9th 2026, With Caution Ahead For 2027 Readouts

Tyra Biosciences is downgraded to "Hold" ahead of key phase 2 SURF302 data for dabogratinib in FGFR3-altered IR-NMIBC patients. Multiple phase 2 readouts, including SURF302, SURF303, and BEACH301, create significant near…

TYRA −0.9% todayRead at source ↗
● PRNewsWireSep 4, 2026 · 08:00 ET
Tyra Biosciences to Host Conference Call on Initial Results of Oral Dabogratinib from the SURF302 Phase 2 Study for IR NMIBC on September 9, 2026

CARLSBAD, Calif., Sept. 4, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in F…

TYRA −0.9% todayRead at source ↗
● Defense WorldAug 31, 2026 · 02:15 ET
Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of “Moderate Buy” by Analysts

Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated th…

TYRA −0.9% todayRead at source ↗
● Defense WorldAug 27, 2026 · 03:35 ET
Algert Global LLC Buys 51,110 Shares of Tyra Biosciences, Inc. $TYRA

Algert Global LLC increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ: TYRA) by 27.2% in the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 239,120 shares of the com…

TYRA −0.9% todayRead at source ↗

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

NVDA33−0.4%
DLB4−3.8%
WDAY4−5.8%

Article counts from the last market-wide feed page, across every symbol we track and not just TYRA · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.